C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/62 (2006.01) A61K 38/28 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C12N 15/17 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2441388
The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human insulin to result in insulin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
L'invention concerne des polypeptides destiné à être administrer notamment à des êtres humains et utiles dans des applications thérapeutiques. Ces polypeptides sont des polypeptides modifiés, la modification résultant en une propension réduite du polypeptide à éliciter une réponse immunitaire lors d'une administration à un sujet humain. L'invention concerne aussi la modification de l'insuline humaine de manière à obtenir des protéines insuline sensiblement non immunogènes ou moins immunogènes que n'importe quelle contrepartie non modifiée lorsqu'elles sont utilisées in vivo.
Carr Francis J.
Carter Graham
Fetherstonhaugh & Co.
Merck Patent Gesellschaft Mit Beschraenkter Haftung
LandOfFree
Modified insulin with reduced immunogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified insulin with reduced immunogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified insulin with reduced immunogenicity will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1808142